| Metric | Grade | Score (0-100) | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | C+ | 62 | Biotech micro-cap in clinical stage; positive price momentum (+3.2% today, +8.7% YTD) offset by profitability constraints (EPS -$1.43) and patent/approval risks | 6–12M |
| SA Quality/Value Composite | C | 58 | No dividend, negative earnings; beta 0.93 suggests moderate volatility; market cap $1.2B points to illiquidity; forward PE unavailable (profitability not visible) | Rolling |
| Zacks Earnings Momentum | D+ | 45 | EPS –$1.43 (loss-making); earnings date unknown; no revenue TTM or growth metrics disclosed; clinical-stage biotech relies on pipeline catalysts, not near-term earnings beat | 6–12M |
| Institutional & Smart Money Flow | B− | 71 | +3.2% intraday change and +8.7% YTD return suggest accumulation; avg volume 1.72M shares; no explicit insider data, but positive technicals imply institutional interest in pipeline catalysts | 1–3M |
| Growth Sustainability & Moat | C | 55 | Biotech sector; no disclosed revenue, EPS growth YoY unavailable; pipeline visibility constrained; 52-week range $7.23–$14.93 shows high volatility; moat unverifiable without clinical/regulatory detail | 6–12M |
| Valuation & Safety (Pre-Penalty) | C+ | 63 | No PE multiple (unprofitable); market cap $1.2B; no target price consensus; week52_high $14.93, current $11.64 = −22% from peak; valuation safety hinges on clinical/regulatory outcomes | 6–12M |
| Penalty Overlay (Liquidity, Crowding, Concentration) | D | 40 | Micro-cap biotech = high idiosyncratic risk; avg volume 1.72M is modest; binary clinical/FDA risks; sector crowding in oncology/immunology unquantified; illiquidity discount applies | Rolling |
| CONFIDENCE SCORE | C | 56 | Data gaps on earnings, profile completeness, revenue, forward PE, target consensus, earnings date; limited visibility on pipeline maturity, trial status, clinical read-outs; assessment based on available quoted metrics only | Rolling |
| Volatility & Drawdown Risk | C+ | 64 | Beta 0.93 (moderate); 52-week range $7.23–$14.93 = 106% spread; current price $11.64 near range midpoint; biotech micro-caps prone to 30–50% swings on trial announcements | 1–3M |
| Crowding Risk Flag | ELEVATED | −15 | Oncology biotech space saturated with similar-stage competitors; retail and thematic biotech ETF interest may inflate near-term demand; exit liquidity at size uncertain | 3–6M |
Oric Pharmaceuticals operates in the clinical-stage oncology/precision medicine space—a crowded segment with well-funded competitors (e.g., Jounce, Syndax, Forty Seven, smaller Incyte/Alnylam satellites). At $1.2B market cap, ORIC sits in the micro-cap cohort where binary clinical/FDA outcomes dominate risk. Peers at similar scale (e.g., JNCE, SNDX, FTSV) trade on pipeline strength, not profitability; ORIC's lack of disclosed revenue and negative EPS place it firmly in the pre-commercialization category. The sector's 2024–2026 tailwind (immuno-oncology, CDK4/6 combinations, kinase inhibitors) provides thematic support, but execution risk remains acute.
1–3 Month Window: Positive technical momentum (+3.2% today, +8.7% YTD) and institutional accumulation (implied by volume/price action) suggest near-term support. Any interim clinical data, partnership news, or financing catalyst could drive 10–20% rallies. Downside risks: trial enrollment slowdowns, competitive readouts, or funding delays could trigger 15–25% corrections.
6–12 Month Window: Valuation and stock performance will likely hinge on major trial readouts, regulatory submissions, or commercialization milestones. If pipeline catalysts are positive, stock could re-test $14.93 (52-week high) and beyond. If trials disappoint or pipeline stalls, downside to $7.23–$9.00 is plausible. Long-term investors should monitor trial timelines, cash burn, and partnership announcements.
Action: Monitor upcoming trial readouts and partnership announcements. Position sizing should reflect micro-cap illiquidity and binary clinical risks. Not appropriate for conservative or income-focused mandates.
ORIC Stock Analysis & Forecast
Is ORIC a Good Investment in 2026?
Our model indicates a neutral outlook based on current fundamentals and momentum.
ORIC Stock Forecast
Based on recent earnings trends, valuation metrics, and sector performance, ORIC shows balanced risk-reward characteristics.
Should You Buy ORIC Now?
Investors should consider market conditions, volatility, and long-term positioning before taking a position in ORIC.